Short answer · Medically reviewed summary · Last updated: 2026-05-08
Ovarian cancer is a significant health concern affecting approximately 1 in 78 women over their lifetime, with an estimated 300,000 new cases diagnosed globally each year. While not classified as a "rare disease" by most global health standards, certain subtypes of ovarian cancer are considered rare, and prevalence estimates can vary due to differences in reporting and the complexity of early-stage diagnosis. Is ovarian cancer considered a rare disease? While ovarian cancer is common enough that it is not typically categorized as a "rare disease," it is often referred to as a "silent killer" because it is frequently diagnosed at an advanced stage.
What is the prevalence of Ovarian cancer?
Prevalence of Ovarian cancer: how many people are affected worldwide, differences by sex and region, with sources.
Ovarian cancer is a significant health concern affecting approximately 1 in 78 women over their lifetime, with an estimated 300,000 new cases diagnosed globally each year. While not classified as a "rare disease" by most global health standards, certain subtypes of ovarian cancer are considered rare, and prevalence estimates can vary due to differences in reporting and the complexity of early-stage diagnosis.
Is ovarian cancer considered a rare disease?
While ovarian cancer is common enough that it is not typically categorized as a "rare disease," it is often referred to as a "silent killer" because it is frequently diagnosed at an advanced stage. The prevalence of ovarian cancer reflects the total number of people living with the disease, which is highly dependent on survival rates and the stage of diagnosis. In the United States, the American Cancer Society estimates that over 200,000 women are currently living with a history of ovarian cancer.
What are the incidence and demographic patterns of ovarian cancer?
The incidence of ovarian cancer is primarily concentrated in adult populations, with the median age of diagnosis being 63 years. It is exclusively a disease of the female reproductive system, though genetic predispositions—such as BRCA1 and BRCA2 mutations—can influence risk across families. Geographic and ethnic variations exist, with higher incidence rates observed in North America and Europe compared to parts of Asia and Africa. Current epidemiological data highlights several critical factors regarding its distribution:
- Age of onset: Rare before age 40; risk increases significantly after menopause.
- Incidence: Approximately 19,000 to 20,000 new cases are diagnosed annually in the U.S. alone.
- Data challenges: Underdiagnosis occurs because early symptoms are often vague and mimic common gastrointestinal issues.
How does the DiseaseMaps community compare to clinical data?
While large-scale epidemiological studies provide the global picture, the 60 people with ovarian cancer currently sharing their experiences on DiseaseMaps.org offer vital, real-world insights. This community data complements clinical statistics by highlighting the patient journey, including the diagnostic delays and quality-of-life challenges that traditional prevalence numbers often fail to capture.
Next steps
- Consult a gynecologic oncologist if you experience persistent bloating, pelvic pain, or difficulty eating.
- Discuss genetic counseling with your physician if there is a strong family history of breast or ovarian cancer.
- Connect with others by joining the ovarian cancer support groups on DiseaseMaps.org to share experiences and coping strategies.
Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of a qualified healthcare provider.
References
- American Cancer Society: Cancer Facts & Figures 2024.
- NIH National Cancer Institute (NCI): Surveillance, Epidemiology, and End Results (SEER) Program.
- World Health Organization (WHO): GLOBOCAN database on global cancer incidence.
- Ovarian Cancer Research Alliance (OCRA): Patient resources and clinical data.
